MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Study of age related neurodegeneration of Cerebellum Basal Ganglia direct subcortical white matter tracts using fixel-based analysis.

    V. Radhakrishnan, C. Gallea, C. Kesavadas, B. Thomas, S. Krishnan, A. Kishore (Trivandrum, India)

    Objective: The goal of the study is to use diffusion weighted imaging to confirm and expand on findings of structural tracks linking cerebellum (CB) and…
  • 2022 International Congress

    Autonomic dysfunction and its correlation witn synucleinopathy: an immunohistological study in Tunisian patients with parkinson disease

    N. Ben Ali, L. Ali, S. Fezai, H. Jamoussi, S. Fray, M. Ben Mahmoud, M. Fredj (Tunis, Tunisia)

    Objective: Identify autonomic digestive symptoms of Parkinson disease (PD)Identify correlations between autonomic dysfunction and alpha-synuclein immunochemical staining in the upper digestive tract. Background: Pathological processes…
  • 2022 International Congress

    Nocturnal attacks of abnormal sleep behaviors and abnormal movements induced by insulin: A case report

    S. El-Jaafary (Cairo, Egypt)

    Objective: To report a case of abnormal sleep behavior associated with hypoglycemia induced by insulin. Background: Hypoglycemia is a serious condition that can be manifested…
  • 2022 International Congress

    NPC1 is not a PD risk factor gene

    G. Barrel, M. Olmedillas, K. Kandaswamy, A. Westenberger, G. Hartmann, C. Klein, P. Bauer, C. Beetz (Rostock, Germany)

    Objective: To test the hypothesis of NPC1 to be a PD risk factor gene. Background: The many etiologies of PD include genetic risk factors. The…
  • 2022 International Congress

    A Case of Neurodegeneration with Brain Iron Accumulation with novel Adaptor Protein-4 M1 subunit mutation

    A. Battineni, D. Vijayakumar (Greenville, USA)

    Objective: To present a patient with clinical and radiological features of neurodegeneration with brain iron accumulation (NBIA) due to a novel variant mutation in adaptor…
  • 2022 International Congress

    Motor and non-motor features of Parkinson’s disease in a large cohort of Gaucher’s disease patients

    E. Monfrini, I. Trezzi, MC. Malaguti, A. Tessitore, A. Barbato, P. Tirelli, F. Spagnolo, MD. Cappellini, E. Cassinerio, I. Motta, F. Carubbi, F. Nascimbeni, L. Borin, A. Di Fonzo (Milano, Italy)

    Objective: To investigate the prevalence of PD motor and non-motor clinical features and to characterize the prodromal phase of PD in a cohort of GD…
  • 2022 International Congress

    COMT polymorphism as a genetic factor in levodopa-induced dyskinesia development in Russian patients with Parkinson’s disease

    G. Akhmadeeva, I. Khidiyatova, I. Gilyazova, S. Umutbaev, O. Kachemaeva, A. Baitimerov, R. Galimova, R. Magzhanov (Ufa, Russian Federation)

    Objective: We examined the influence of single nucleotide polymorphisms (SNPs) in specific genes on levodopa-induced dyskinesia development in Parkinson’s disease patients Background: Levodopa-induced dyskinesia (LID)…
  • 2022 International Congress

    Phase 2 study evaluating safety, PK/PD, biomarkers, and efficacy of ANX005 in patients with Huntington’s disease (HD)

    R. Kumar, D. Claassen, A. Mongan, A. Grover, B. Hoehn, P. Lin, R. Arnold, E. Cahir-Mcfarland, T. Yednock, S. Keswani (Englewood, USA)

    Objective: To assess the safety, PK/PD, exploratory biomarkers, and efficacy of ANX005 in patients with, or at risk for, manifest HD. Background: Increased complement activation…
  • 2022 International Congress

    Levodopa Carbidopa Intestinal Gel in Patients with Deep Brain Stimulation in Parkinson’s disease- First case series from Middle-East Region

    S. Mittal, A. Aldakheel, W. Mohammed, T. Alkhairallah, B. Klassen, M. Thomas, T. Maiti, S. Wasti (Abu Dhabi, United Arab Emirates)

    Objective: The objective is to report unique and challenging cases, who had successful control of Parkinson’s disease (PD) symptoms with combination therapy of Deep Brain…
  • 2022 International Congress

    Deep brain stimulation of the subthalamic nucleus under general vs local anesthesia

    S. Asriyants, A. Tomskiy, A. Gamaleya, A. Poddubskaya, A. Sedov, I. Pronin (Moscow, Russian Federation)

    Objective: The aim of the study was to compare outcomes of the deep brain stimulation (DBS) of the subthalamic nucleus (STN) in patients with Parkinson’s…
  • « Previous Page
  • 1
  • …
  • 416
  • 417
  • 418
  • 419
  • 420
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Safety and Tolerability of a Ketone Supplement in Parkinson's Disease
  • Successful external defibrillation in a patient with bilateral deep brain stimulation
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley